论文部分内容阅读
兴奋性氨基酸类神经递质对中枢神经缺血性损害具有明显加重作用,这种兴奋性神经冲动大量传入对神经元有明显的损伤作用。同时,这种兴奋性递质可以被特异性拮抗剂所对抗。实验中竞争性、非竞争性N-甲基-D-天冬氨酸(NMDA)拮抗剂在中枢神经缺血中都具有明显的延迟治疗作用。竞争性NM-DA拮抗剂在实验中显示出更好的治疗效果和较少的副作用。这次研究的目的就是通过将CGS-19755和LY233055两种新近生产的胃肠道外给药的NM-DA竞争性拮抗剂用于可逆性脑缺血中作延迟治疗剂使用,以了解对缺血时的神经保护作用。实验中动物仅出现轻微的镇静和共济失调副作用。
Excitatory amino acid neurotransmitters have obvious aggravating effect on central nervous ischemic damage. The large amount of excitatory nerve impulses has a significant damage on neurons. At the same time, this excitatory neurotransmitter can be antagonized by specific antagonists. In the experiment, competitive, noncompetitive N-methyl-D-aspartate (NMDA) antagonists all had a significant delay in the treatment of CNS ischemia. Competitive NM-DA antagonists have shown better therapeutic efficacy and fewer side effects in experiments. The aim of this study was to investigate the effect of CGS-19755 and LY233055, two newly produced parenteral NM-DA competitive antagonists, on delayed ischemic reperfusion in reversible cerebral ischemia When the neuroprotective effect. In the experiment animals showed only mild sedation and ataxia side effects.